Review

† Author for correspondence

Department of Cell Stress Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.

Email the corresponding author at katerina.gurova@roswellpark.org

Published Online:15 Dec 2009https://doi.org/10.2217/fon.09.127

Abstract

Most of the anticancer chemotherapeutic drugs that are broadly and successfully used today are DNA-damaging agents. Targeting of DNA has been proven to cause relatively potent and selective destruction of tumor cells. However, the clinical potential of DNA-damaging agents is limited by the adverse side effects and increased risk of secondary cancers that are consequences of the agents’ genotoxicity. In this review, we present evidence that those agents capable of targeting DNA without inducing DNA damage would not be limited in these ways, and may be as potent as DNA-damaging agents in the killing of tumor cells. We use as an example literature data and our own research of the well-known antimalarial drug quinacrine, which binds to DNA without inducing DNA damage, yet modulates a number of cellular pathways that impact tumor cell survival.

Keywords:

Bibliography

1 Watson JD, Crick FHC: A Structure for deoxyribose nucleic acid. Nature171,737–738 (1953).
Medline CASGoogle Scholar
2 Boer DR, Canals A, Coll M: DNA-binding drugs caught in action: the latest 3D pictures of drug-DNA complexes. Dalton Trans. (3),399–414 (2009).
MedlineGoogle Scholar
3 Pindur U, Jansen M, Lemster T: Advances in DNA-ligands with groove binding, intercalating and/or alkylating activity: chemistry, DNA-binding and biology. Curr. Med. Chem.12(24),2805–2847 (2005).
Medline CASGoogle Scholar
4 Strekowski L, Wilson B: Noncovalent interactions with DNA: an overview. Mutat. Res.623(1–2),3–13 (2007).
Medline CASGoogle Scholar
5 Ferguson LR, Denny WA: Genotoxicity of non-covalent interactions: DNA intercalators. Mutat. Res.623(1–2),14–23 (2007).
Medline CASGoogle Scholar
6 Snyder RD: Assessment of atypical DNA intercalating agents in biological and in silico systems. Mutat. Res.623(1–2),72–82 (2007).
Medline CASGoogle Scholar
7 Bielawski K, Bielawska A: Small-molecule based delivery systems for alkylating antineoplastic compounds. ChemMedChem3(4),536–542 (2008).
Medline CASGoogle Scholar
8 Martinez R, Chacon-Garcia L: The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work. Curr. Med. Chem.12(2),127–151 (2005).
Medline CASGoogle Scholar
9 Antonini I, Polucci P, Magnano A et al.: Design, synthesis, and biological properties of new bis (acridine-4-carboxamides) as anticancer agents. J. Med. Chem.46(14),3109–3115 (2003).
Medline CASGoogle Scholar
10 Antonini I: DNA-binding antitumor agents: from pyrimido[5,6,1-de]acridines to other intriguing classes of acridine derivatives. Curr. Med. Chem.9(18),1701–1716 (2002).
Medline CASGoogle Scholar
11 Demeunynck M, Charmantray F, Martelli A: Interest of acridine derivatives in the anticancer chemotherapy. Curr. Pharm. Des.7(17),1703–1724 (2001).
Medline CASGoogle Scholar
12 Albert A: The Acridines: Their Preparation, Physical, Chemical, and Biological Properties and Uses. St Martin’s Press, NY, USA (1951).
Google Scholar
13 Mellanby E: Report on work carried out in the pharmacological laboratory, Sheffield University. Brit. Emp. Cancer C.10,102 (1933).
Google Scholar
14 Lasnitzki I, Wilkinson J: The effect of acridine derivatives on growth and mitoses of cells in vitroBr. J. Cancer2,369–375 (1948).
Medline CASGoogle Scholar
15 Wallace DJ: The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin. Arthritis Rheum.18(4),282–296 (1989).
Medline CASGoogle Scholar
16 Young MD, Eyles DE: The efficacy of chloroquine, quinacrine, quinine and totaquine in the treatment of Plasmodium malariae infections (quartan malaria). Am. J. Trop. Med. Hyg.28(1),23–28 (1948).
Medline CASGoogle Scholar
17 Winckel CW: The efficacy of quinacrine and quinine in the treatment of Plasmodium malariae infections. Doc. Neerl. Indones. Morbis. Trop.1(1),93–96 (1949).
Medline CASGoogle Scholar
18 Shannon J, Earl D, Brodie B et al.: The pharmacological basis for rational use of atabrine in the treatment of malaria. J. Pharmacol. Exp. Ther.81,307–330 (1944).
CASGoogle Scholar
19 no.153 OotSGCL. The drug treatment of malaria: suppressive and clinical. JAMA123,205–208 (1943).
Google Scholar
20 Goodman L, Gilamn A: The Pharmacological Basis of Therapeutics (2nd Edition). Macmillan, NY, USA (1954).
Google Scholar
21 Wolfe MS: The treatment of intestinal protozoan infections. Med. Clin. North. Am.66(3),707–720 (1982).
Medline CASGoogle Scholar
22 Wolfe MS: Giardiasis. Clin. Microbiol. Rev.5(1),93–100 (1992).
Medline CASGoogle Scholar
23 Upcroft P, Upcroft JA: Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev.14(1),150–164 (2001).
Medline CASGoogle Scholar
24 Page F: Treatment of lupus erythematosus with mepacrine. Lancet2(6687),755–758 (1951).
Medline CASGoogle Scholar
25 Freedman A, Bach F: Mepacrine and rheumatoid arthritis. Lancet2(6729),321 (1952).
Medline CASGoogle Scholar
26 Voog R, Chouteau J, Marchal A, Cabanel G: [Asthma therapy with a combination of synthetic antimalarials (83 cases)]. Presse Med.77(53),1995 (1969).
Medline CASGoogle Scholar
27 Zuehlke RL, Lillis PJ, Tice A: Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine. Int. J. Dermatol.20(1),57–61 (1981).
Medline CASGoogle Scholar
28 Sokol RJ, Lichtenstein PK, Farrell MK: Quinacrine hydrochloride-induced yellow discoloration of the skin in children. Pediatrics69(2),232–233 (1982).
Medline CASGoogle Scholar
29 Perk D: Mepacrine psychosis. J. Ment. Sci.93(393),756–771 (1947).
Medline CASGoogle Scholar
30 Sapp OL 3rd: Toxic psychosis due to quinarcrine and chloroquine. JAMA187,373–375 (1964).
MedlineGoogle Scholar
31 Lindenmayer JP, Vargas P: Toxic psychosis following use of quinacrine. J. Clin. Psychiatry42(4),162–164 (1981).
Medline CASGoogle Scholar
32 Lown B, Graboys TB, Podrid PJ, Cohen BH, Stockman MB, Gaughan CE: Effect of a digitalis drug on ventricular premature beats. N. Engl. J. Med.296(6),301–306 (1977).
Medline CASGoogle Scholar
33 Carr RE, Henkind P, Rothfield N, Siegel IM: Ocular toxicity of antimalarial drugs. Long-term follow-up. Am. J. Ophthalmol.66(4),738–744 (1968).
Medline CASGoogle Scholar
34 Dubois E: Lupus Erythematosus. University of Southern California, CA, USA (1976).
Google Scholar
35 Biro L, Leone N: Aplastic anemia induced by quinacrine. Arch. Dermatol.92(5),574–576 (1965).
Medline CASGoogle Scholar
36 Heimpel H, Heit W: Drug-induced aplastic anaemia: clinical aspects. Clin. Haematol.9(3),641–662 (1980).
Medline CASGoogle Scholar
37 Atkin NB: Y chromosomes and quinacrine fluorescence technique. BMJ4(5727),118 (1970).
Medline CASGoogle Scholar
38 Caspersson T, Zech L, Johansson C, Modest EJ: Identification of human chromosomes by DNA-binding fluorescent agents. Chromosoma30(2),215–227 (1970).
Medline CASGoogle Scholar
39 Gurova KV, Hill JE, Guo C et al.: Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proc. Natl Acad. Sci. USA102(48),17448–17453 (2005).
Medline CASGoogle Scholar
40 Bourdon JC: p53 and its isoforms in cancer. Br. J. Cancer97(3),277–282 (2007).
Medline CASGoogle Scholar
41 Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV: p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res.64(6),1951–1958 (2004).
Medline CASGoogle Scholar
42 Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene24(17),2899–2908 (2005).
Medline CASGoogle Scholar
43 Riemenschneider MJ, Buschges R, Wolter M et al.: Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res.59(24),6091–6096 (1999).
Medline CASGoogle Scholar
44 Woynarowski JM, Bartoszek A, Konopa J: DNA damage in HeLa s3 cells by an antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines. Chem. Biol. Interact.49(3),311–328 (1984).
Medline CASGoogle Scholar
45 Hour TC, Lee CC, Lin JK: A new mutagenicity assay method for frameshift mutagens based on deleting or inserting a guanosine nucleotide in the β-lactamase gene. Mutagenesis10(5),433–438 (1995).
Medline CASGoogle Scholar
46 Tomosaka H, Omata S, Anzai K: Enhancement of mutagenic activity of 9-aminoacridine by introducing a nitro group into the molecule. Biosci. Biotechnol. Biochem.58(8),1420–1423 (1994).
Medline CASGoogle Scholar
47 Covey JM, Kohn KW, Kerrigan D, Tilchen EJ, Pommier Y: Topoisomerase II-mediated DNA damage produced by 4´-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res.48(4),860–865 (1988).
Medline CASGoogle Scholar
48 Ahmed KM, Li JJ: ATM–NF-κB connection as a target for tumor radiosensitization. Curr. Cancer Drug Targets7(4),335–342 (2007).
Medline CASGoogle Scholar
49 Wu ZH, Shi Y, Tibbetts RS, Miyamoto S: Molecular linkage between the kinase ATM and NF-κB signaling in response to genotoxic stimuli. Science311(5764),1141–1146 (2006).
Medline CASGoogle Scholar
50 Habraken Y, Piette J: NF-κB activation by double-strand breaks. Biochem. Pharmacol.72(9),1132–1141 (2006).
Medline CASGoogle Scholar
51 Snyder RD, Hendry LB: Toward a greater appreciation of noncovalent chemical/DNA interactions: application of biological and computational approaches. Environ. Mol. Mutagen.45(2–3),100–105 (2005).
Medline CASGoogle Scholar
52 Finlay GJ, Wilson WR, Baguley BC: Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. Eur. J. Cancer Clin. Oncol.25(12),1695–1701 (1989).
Medline CASGoogle Scholar
53 Mitchel RE, Burchart P, Wyatt H: A lower dose threshold for the in vivo protective adaptive response to radiation. Tumorigenesis in chronically exposed normal and Trp53 heterozygous C57BL/6 mice. Radiat. Res.170(6),765–775 (2008).
Medline CASGoogle Scholar
54 Clarke JJ, Sokal DC, Cancel AM et al.: Re-evaluation of the mutagenic potential of quinacrine dihydrochloride dihydrate. Mutat. Res.494(1–2),41–53 (2001).
Medline CASGoogle Scholar
55 Cook TM, Goldman CK: Hycanthone and its congeners as bacterial mutagens. J. Bacteriol.122(2),549–556 (1975).
Medline CASGoogle Scholar
56 Ames B, Whitfield H: Frameshift mutagenesis in Salmonella. Cold Spring Harb. Symp. Quant. Biol.31,3221–3225 (1966).
Google Scholar
57 Gasc AM, Sicard AM: Genetic studies of acridine-induced mutants in Streptococcus pneumoniae. Genetics90(1),1–18 (1978).
Medline CASGoogle Scholar
58 McCarroll NE, Piper CE, Keech BH: An E. coli microsuspension assay for the detection of DNA damage induced by direct-acting agents and promutagens. Environ. Mutagen.3(4),429–444 (1981).
Medline CASGoogle Scholar
59 Jenssen D, Ramel C, Gothe R: The induction of micronuclei by frameshift mutagens at the time of nucleus expulsion in mouse erythroblasts. Mutat. Res.26(6),553–555 (1974).
Medline CASGoogle Scholar
60 Krishnaja AP, Chauhan PS: Quinacrine dihydrochloride, the non-surgical female sterilant induces dicentrics, rings, and marker chromosomes in human peripheral blood lymphocytes treated in vitro: a preliminary report. Mutat. Res.466(1),43–50 (2000).
Medline CASGoogle Scholar
61 Snyder RD, Arnone MR: Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutat. Res.503(1–2),21–35 (2002).
Medline CASGoogle Scholar
62 Neubort S, Liebeskind D, Mendez F, Elequin F, Hsu KC, Bases R: Morphological transformation, DNA strand separation, and antinucleoside immunoreactivity following exposure of cells to intercalating drugs. Mol. Pharmacol.21(3),739–743 (1982).
Medline CASGoogle Scholar
63 Sevag MG: Prevention of the emergence of antibiotic-resistant strains of bacteria by atabrine. Arch. Biochem. Biophys.108,85–88 (1964).
Medline CASGoogle Scholar
64 Sevag MG, Ashton B: Evolution and prevention of drug-resistance. Nature203,1323–1326 (1964).
Medline CASGoogle Scholar
65 Johnson HG, Bach MK: Apparent antimutagenic activity of quinacrine hydrochloride in Detroit-98 human sternal marrow cells grown in culture. Cancer Res.29(7),1367–1370 (1969).
Medline CASGoogle Scholar
66 Bach MK: Reduction in the frequency of mutation to resistance to cytarabine in L1210 murine leukemic cells by treatment with quinacrine hydrochloride. Cancer Res.29(10),1881–1885 (1969).
Medline CASGoogle Scholar
67 Johnson HG, Bach MK: The antimutagenic action of polyamines: suppression of the mutagenic action of an E. coli mutator gene and of 2-aminopurine. Proc. Natl Acad. Sci. USA55(6),1453–1456 (1966).
Medline CASGoogle Scholar
68 Koranda FC: Antimalarials. J. Am. Acad. Dermatol.4(6),650–655 (1981).
Medline CASGoogle Scholar
69 Zipper J, Trujillo V: 25 years of quinacrine sterilization experience in Chile: review of 2,592 cases. Int. J. Gynaecol. Obstet.,83(Suppl. 2),S23–S29 (2003).
CASGoogle Scholar
70 Kessel E: 100,000 quinacrine sterilizations. Adv. Contracept.12(2),69–76 (1996).
Medline CASGoogle Scholar
71 Cancel AM, Smith T, Rehkemper U, Dillberger JE, Sokal D, McClain RM: A one-year neonatal mouse carcinogenesis study of quinacrine dihydrochloride. Int. J. Toxicol.25(2),109–118 (2006).
Medline CASGoogle Scholar
72 Reyes S, Rembao D, Sotelo J: The antimalarials quinacrine and chloroquine potentiate the transplacental carcinogenic effect of ethylnitrosourea on ependymal cells. Brain Tumor Pathol.18(2),83–87 (2001).
Medline CASGoogle Scholar
73 Dutta P, Karmali R, Pinto JT, Rivlin RS: Enhanced growth of mammary adenocarcinoma in rats by chloroquine and quinacrine. Cancer Lett.76(2–3),113–119 (1994).
Medline CASGoogle Scholar
74 Furukawa F, Nishikawa A, Imazawa T, Kasahara K, Takahashi M: Enhancing effects of quinacrine on development of hepatopancreatic lesions in N-nitrosobis(2-oxopropyl)amine-initiated hamsters. Jpn. J. Cancer Res.89(2),131–136 (1998).
Medline CASGoogle Scholar
75 Neznanov N, Gorbachev AV, Neznanova L et al.: Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle8(23),1–11 (2009).
MedlineGoogle Scholar
76 Sors A, Jean-Louis F, Pellet C et al.: Down-regulating constitutive activation of the NF-κB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood107(6),2354–2363 (2006).
Medline CASGoogle Scholar
77 Schwartz SA, Hernandez A, Mark Evers B: The role of NF-κB/IκB proteins in cancer: implications for novel treatment strategies. Surg. Oncol.8(3),143–153 (1999).
Medline CASGoogle Scholar
78 Rossi A, Ciafre S, Balsamo M, Pierimarchi P, Santoro MG: Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res.66(15),7678–7685 (2006).
Medline CASGoogle Scholar
79 McAnulty JF, Waller K: The effect of quinacrine on oxidative stress in kidney tissue stored at low temperature after warm ischemic injury. Cryobiology39(3),197–204 (1999).
Medline CASGoogle Scholar
80 Lochner A, Genade S, Tromp E, Theron S, Trollip G: Postcardioplegic myocardial recovery: effects of halothane, nifedipine, HOE 694, and quinacrine. Cardiovasc. Drugs Ther.12(3),267–277 (1998).
Medline CASGoogle Scholar
81 Bugge E, Gamst TM, Hegstad AC, Andreasen T, Ytrehus K: Mepacrine protects the isolated rat heart during hypoxia and reoxygenation – but not by inhibition of phospholipase A2. Basic Res. Cardiol.92(1),17–24 (1997).
Medline CASGoogle Scholar
82 Estevez AY, Phillis JW: The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion. Brain Res.752(1–2),203–208 (1997).
Medline CASGoogle Scholar
83 Chiariello M, Ambrosio G, Cappelli-Bigazzi M et al.: Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion. Am. Heart J.120(4),801–807 (1990).
Medline CASGoogle Scholar
84 Moffat MP, Tsushima RG: Functional and electrophysiological effects of quinacrine on the response of ventricular tissues to hypoxia and reoxygenation. Can. J. Physiol. Pharmacol.67(8),929–935 (1989).
Medline CASGoogle Scholar
85 van Bilsen M, van der Vusse GJ, Willemsen PH, Coumans WA, Roemen TH, Reneman RS: Effects of nicotinic acid and mepacrine on fatty acid accumulation and myocardial damage during ischemia and reperfusion. J. Mol. Cell. Cardiol.22(2),155–163 (1990).
Medline CASGoogle Scholar
86 Gonzalez Padron A, de Toranzo EG, Castro JA: Late preventive effects of quinacrine on carbon tetrachloride induced liver necrosis. Arch. Toxicol.67(6),386–391 (1993).
Medline CASGoogle Scholar
87 al-Bayati ZA, Stohs SJ: The possible role of phospholipase A2 in hepatic microsomal lipid peroxidation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Arch. Environ. Contam. Toxicol.20(3),361–365 (1991).
Medline CASGoogle Scholar
88 Stacey NH, Klaassen CD: Effects of phospholipase A2 inhibitors on diethyl maleate-induced lipid peroxidation and cellular injury in isolated rat hepatocytes. J. Toxicol. Environ. Health9(3),439–450 (1982).
Medline CASGoogle Scholar
89 Ong WY, Lu XR, Horrocks LA, Farooqui AA, Garey LJ: Induction of astrocytic cytoplasmic phospholipase A2 and neuronal death after intracerebroventricular carrageenan injection, and neuroprotective effects of quinacrine. Exp. Neurol.183(2),449–457 (2003).
Medline CASGoogle Scholar
90 Wang XS, Ong WY, Connor JR: Quinacrine attenuates increases in divalent metal transporter-1 and iron levels in the rat hippocampus, after kainate-induced neuronal injury. Neuroscience120(1),21–29 (2003).
Medline CASGoogle Scholar
91 Tariq M, Khan HA, Al Moutaery K, Al Deeb S: Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. Brain Res. Bull.54(1),77–82 (2001).
Medline CASGoogle Scholar
92 Smith HJ, Tisdale MJ: Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes. Br. J. Cancer89(9),1783–1788 (2003).
Medline CASGoogle Scholar
93 Kohjimoto Y, Kennington L, Scheid CR, Honeyman TW: Role of phospholipase A2 in the cytotoxic effects of oxalate in cultured renal epithelial cells. Kidney Int.56(4),1432–1441 (1999).
Medline CASGoogle Scholar
94 Hossain M, Giri P, Kumar GS: DNA intercalation by quinacrine and methylene blue: a comparative binding and thermodynamic characterization study. DNA Cell Biol.27(2),81–90 (2008).
Medline CASGoogle Scholar
95 Nardo L, Bondani M, Andreoni A: DNA-ligand binding mode discrimination by characterizing fluorescence resonance energy transfer through lifetime measurements with picosecond resolution. Photochem. Photobiol.84(1),101–110 (2008).
Medline CASGoogle Scholar
96 Aloisi GG, Amelia M, Barbafina A et al.: DNA cleavage induced by photoexcited antimalarial drugs: a photophysical and photobiological study. Photochem. Photobiol.83(3),664–674 (2007).
Medline CASGoogle Scholar
97 Aslanoglu M, Ayne G: Voltammetric studies of the interaction of quinacrine with DNA. Anal. Bioanal. Chem.380(4),658–663 (2004).
Medline CASGoogle Scholar
98 Jones RL, Lanier AC, Keel RA, Wilson WD: The effect of ionic strength on DNA-ligand unwinding angles for acridine and quinoline derivatives. Nucleic Acids Res.8(7),1613–1624 (1980).
Medline CASGoogle Scholar
99 Jones RL, Davidson MW, Wilson WD: Comparative viscometric analysis of the interaction of chloroquine and quinacrine with superhelical and sonicated DNA. Biochim. Biophys. Acta,561(1),77–84 (1979).
Medline CASGoogle Scholar
100 Bewley CA, Gronenborn AM, Clore GM: Minor groove-binding architectural proteins: structure, function, and DNA recognition. Annu. Rev. Biophys. Biomol. Struct.27,105–131 (1998).
Medline CASGoogle Scholar
101 Moravek Z, Neidle S, Schneider B: Protein and drug interactions in the minor groove of DNA. Nucleic Acids Res.30(5),1182–1191 (2002).
Medline CASGoogle Scholar
102 Kahne D: Strategies for the design of minor groove binders: a re-evaluation based on the emergence of site-selective carbohydrate binders. Chem. Biol.2(1),7–12 (1995).
Medline CASGoogle Scholar
103 Cai X, Gray PJ Jr, Von Hoff DD: DNA minor groove binders: back in the groove. Cancer Treat Rev.35(5),437–450 (2009).
Medline CASGoogle Scholar
104 Scaria PV, Craig JC, Shafer RH: Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: implications for stereoselective metabolism. Biopolymers33(6),887–895 (1993).
Medline CASGoogle Scholar
105 Denny WA: DNA-intercalating ligands as anti-cancer drugs: prospects for future design. Anticancer Drug Des.4(4),241–263 (1989).
Medline CASGoogle Scholar
106 Albertini S, Chetelat AA, Miller B et al.: Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems. Mutagenesis10(4),343–351 (1995).
Medline CASGoogle Scholar
107 Snyder RD, Gillies PJ: Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ. Mol. Mutagen.40(4),266–276 (2002).
Medline CASGoogle Scholar
108 Wolfe AD, Cook TM, Hahn FE: Antibacterial nitroacridine, Nitroakridin 3582: binding to nucleic acids in vitro and effects on selected cell-free model systems of macromolecular biosynthesis. J. Bacteriol.108(3),1026–1033 (1971).
Medline CASGoogle Scholar
109 Nelson SM, Ferguson LR, Denny WA: Non-covalent ligand/DNA interactions: minor groove binding agents. Mutat. Res.623(1–2), 24–40 (2007).
MedlineGoogle Scholar
110 Brosh RM Jr, Karow JK, White EJ, Shaw ND, Hickson ID, Bohr VA. Potent inhibition of werner and bloom helicases by DNA minor groove binding drugs. Nucleic Acids Res.28(12),2420–2430 (2000).
Medline CASGoogle Scholar
111 Ghersa P, Whelan J, Cambet Y, DeLamarter JF, Hooft van Huijsduijnen R: Distamycin prolongs E-selectin expression by interacting with a specific NF-κB-HMG-I(Y) binding site in the promoter. Nucleic Acids Res.25(2),339–346 (1997).
Medline CASGoogle Scholar
112 Takamiya R, Baron RM, Yet SF, Layne MD, Perrella MA: High mobility group A1 protein mediates human nitric oxide synthase 2 gene expression. FEBS Lett.582(5),810–814 (2008).
Medline CASGoogle Scholar
113 Goodwin GH, Sanders C, Johns EW: A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem.38(1),14–19 (1973).
Medline CASGoogle Scholar
114 Thomas JO, Travers AA: HMG1 and 2, and related ‘architectural’ DNA-binding proteins. Trends Biochem. Sci.26(3),167–174 (2001).
Medline CASGoogle Scholar
115 Juo ZS, Chiu TK, Leiberman PM, Baikalov I, Berk AJ, Dickerson RE: How proteins recognize the TATA box. J. Mol. Biol.261(2),239–254 (1996).
Medline CASGoogle Scholar
116 Lewis M, Chang G, Horton NC et al.: Crystal structure of the lactose operon repressor and its complexes with DNA and inducer. Science271(5253),1247–1254 (1996).
Medline CASGoogle Scholar
117 Schultz S, Sheields G, Steitz T: Crystal structure of a CAP–DNA complex: the DNA is bent by 90 degrees. Science253,1001–1007 (1991).
Medline CASGoogle Scholar
118 Schumacher M, Choi K, Zalkin H, Brennan R: Crystal structure of LacI member, PuR, bound to DNA: minor groove binding by a helices. Science256,763–770 (1994).
Google Scholar
119 Farnet CM, Bushman FD: HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell88(4),483–492 (1997).
Medline CASGoogle Scholar
120 Thanos D, Maniatis T: Virus induction of human IFN-b gene expression requires the assembly of an enhanceosome. Cell83(7),1091–1100 (1995).
Medline CASGoogle Scholar
121 Chen FE, Ghosh G: Regulation of DNA binding by Rel/NF-κB transcription factors: structural views. Oncogene18(49),6845–6852 (1999).
Medline CASGoogle Scholar
122 Bianchi ME, Agresti A: HMG proteins: dynamic players in gene regulation and differentiation. Curr. Opin. Genet. Dev.15(5),496–506 (2005).
Medline CASGoogle Scholar
123 Reinberg D, Sims RJ 3rd: De facto nucleosome dynamics. J. Biol. Chem.281(33),23297–23301 (2006).
Medline CASGoogle Scholar
124 Agresti A, Bianchi ME: HMGB proteins and gene expression. Curr. Opin. Genet. Dev.13(2),170–178 (2003).
Medline CASGoogle Scholar
125 Martinez Hoyos J, Fedele M, Battista S et al.: Identification of the genes up- and down-regulated by the high mobility group A1 (HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. Cancer Res.64(16),5728–5735 (2004).
MedlineGoogle Scholar
126 Chau KY, Keane-Myers AM, Fedele M et al.: IFN-g gene expression is controlled by the architectural transcription factor HMGA1. Int. Immunol.17(3),297–306 (2005).
Medline CASGoogle Scholar
127 Whitley MZ, Thanos D, Read MA, Maniatis T, Collins T: A striking similarity in the organization of the E-selectin and b interferon gene promoters. Mol. Cell. Biol.14(10),6464–6475 (1994).
Medline CASGoogle Scholar
128 Lewis H, Kaszubska W, DeLamarter JF, Whelan J: Cooperativity between two NF-κB complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine-induced expression of the E-selectin promoter. Mol. Cell. Biol.14(9),5701–5709 (1994).
Medline CASGoogle Scholar
129 Treff NR, Dement GA, Adair JE et al.: Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells. Oncogene23(52),8557–8562 (2004).
Medline CASGoogle Scholar
130 Attema JL, Reeves R, Murray V et al.: The human IL-2 gene promoter can assemble a positioned nucleosome that becomes remodeled upon T cell activation. J. Immunol.,169(5),2466–2476 (2002).
Medline CASGoogle Scholar
131 Foti D, Chiefari E, Fedele M et al.: Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat. Med.11(7),765–773 (2005).
Medline CASGoogle Scholar
132 Agresti A, Scaffidi P, Riva A, Caiolfa VR, Bianchi ME: GR and HMGB1 interact only within chromatin and influence each other’s residence time. Mol. Cell.18(1),109–121 (2005).
Medline CASGoogle Scholar
133 Saunders A, Werner J, Andrulis ED et al.: Tracking FACT and the RNA polymerase II elongation complex through chromatin in vivo. Science301(5636),1094–1096 (2003).
Medline CASGoogle Scholar
134 Abde l-Latif AA, Smith JP, Akhtar RA: Studies on the mechanism of alteration by propranolol and mepacrine of the metabolism of phosphoinositides and other glycerolipids in the rabbit iris muscle. Biochem. Pharmacol.32(24),3815–3821 (1983).
Medline CASGoogle Scholar
135 Dise CA, Burch JW, Goodman DB: Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid. J. Biol. Chem.257(9),4701–4704 (1982).
Medline CASGoogle Scholar
136 Mustonen P, Lehtonen JY, Kinnunen PK: Binding of quinacrine to acidic phospholipids and pancreatic phospholipase A2. Effects on the catalytic activity of the enzyme. Biochemistry37(35),12051–12057 (1998).
Medline CASGoogle Scholar
137 Jain MK, Yu BZ, Rogers J, Ranadive GN, Berg OG: Interfacial catalysis by phospholipase A2: dissociation constants for calcium, substrate, products, and competitive inhibitors. Biochemistry30(29),7306–7317 (1991).
Medline CASGoogle Scholar
138 Loffler BM, Bohn E, Hesse B, Kunze H: Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Biochim. Biophys. Acta.835(3),448–455 (1985).
Medline CASGoogle Scholar
139 Schiess K, Kaszkin M, Jordan P, Seidler L, Kinzel V: Mobilization of diacylglycerol in intact HeLa cells by exogenous phospholipase C from Cl. perfringens is accompanied by release of fatty acids including arachidonic acid. Biochim. Biophys. Acta.1137(1),82–94 (1992).
Medline CASGoogle Scholar
140 Ahmed A, Cameron IT, Ferriani RA, Smith SK: Activation of phospholipase A2 and phospholipase C by endothelin-1 in human endometrium. J. Endocrinol.135(2),383–390 (1992).
Medline CASGoogle Scholar
141 Torda T, Yamaguchi I, Hirata F, Kopin IJ, Axelrod J: Quinacrine-blocked desensitization of adrenoceptors after immobilization stress or repeated injection of isoproterenol in rats. J. Pharmacol. Exp. Ther.16(2),334–338 (1981).
Google Scholar
142 Yamada K, Okano Y, Miura K, Nozawa Y: A major role for phospholipase A2 in antigen-induced arachidonic acid release in rat mast cells. Biochem. J.247(1),95–99 (1987).
Medline CASGoogle Scholar
143 Xiao YF, Zeind AJ, Kaushik V, Perreault-Micale CL, Morgan JP: Mechanism of suppression of cardiac L-type Ca(²⁺) currents by the phospholipase A(2) inhibitor mepacrine. Eur. J. Pharmacol.399(2–3),107–116 (2000).
Medline CASGoogle Scholar
144 Eldefrawi M: Interactions of drug with the nicotinic acetylcholine receptor and its ionic channel. Prog. Clin. Biol. Res.27,63–71 (1979).
Medline CASGoogle Scholar
145 Flamand N, Plante H, Picard S, Laviolette M, Borgeat P: Histamine-induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMP. Br. J. Pharmacol.141(4),552–561 (2004).
Medline CASGoogle Scholar
146 Zamora JM, Pearce HL, Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol.33(4),454–462 (1988).
Medline CASGoogle Scholar
147 Beckman JK, Borowitz SM, Burr IM: The role of phospholipase A activity in rat liver microsomal lipid peroxidation. J. Biol. Chem.262(4),1479–1484 (1987).
Medline CASGoogle Scholar
148 Becker BN, Cheng HF, Harris RC: Apical ANG II-stimulated PLA2 activity and Na⁺ flux: a potential role for Ca²⁺-independent PLA2. Am. J. Physiol.273(4 Pt 2),F554–F562 (1997).
Medline CASGoogle Scholar
149 Filippov A, Skatova G, Porotikov V, Kobrinsky E, Saxon M: Ca²⁺-antagonistic properties of phospholipase A2 inhibitors, mepacrine and chloroquine. Gen. Physiol. Biophys.8(2),113–118 (1989).
Medline CASGoogle Scholar
150 Volpi M, Sha’afi RI, Epstein PM, Andrenyak DM, Feinstein MB: Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin. Proc. Natl Acad. Sci. USA78(2),795–799 (1981).
Medline CASGoogle Scholar
151 Blackwell GJ, Duncombe WG, Flower RJ, Parsons MF, Vane JR: The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br. J. Pharmacol.59(2),353–366 (1977).
Medline CASGoogle Scholar
152 Crouch MF, Roberts ML, Tennes KA: Mepacrine inhibition of bradykinin-induced contractions of the rabbit ear vein. Agents Actions11(4),330–334 (1981).
Medline CASGoogle Scholar
153 Becker BN, Harris RC: A potential mechanism for proximal tubule angiotensin II-mediated sodium flux associated with receptor-mediated endocytosis and arachidonic acid release. Kidney Int. Suppl.57,S66–S72 (1996).
Medline CASGoogle Scholar
154 Locati M, Zhou D, Luini W, Evangelista V, Mantovani A, Sozzani S: Rapid induction of arachidonic acid release by monocyte chemotactic protein-1 and related chemokines. Role of Ca²⁺ influx, synergism with platelet-activating factor and significance for chemotaxis. J. Biol. Chem.269(7),4746–4753 (1994).
Medline CASGoogle Scholar
155 Du X, Harris SJ, Tetaz TJ, Ginsberg MH, Berndt MC: Association of a phospholipase A2 (14–3–3 protein) with the platelet glycoprotein Ib-IX complex. J. Biol. Chem.269(28),18287–18290 (1994).
Medline CASGoogle Scholar
156 Palmetshofer A, Robson SC, Nehls V: Lysophosphatidic acid activates nuclear factor kappa B and induces proinflammatory gene expression in endothelial cells. Thromb. Haemost.82(5),1532–1537 (1999).
Medline CASGoogle Scholar
157 Diaz GJ, Squires EJ: Role of aldehyde oxidase in the hepatic in vitro metabolism of 3-methylindole in pigs. J. Agric. Food Chem.48(3),833–837 (2000).
Medline CASGoogle Scholar
158 Renton KW, Mannering GJ: Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. Biochem. Biophys. Res. Commun.73(2),343–348 (1976).
Medline CASGoogle Scholar
159 Thabrew MI, Ioannides C: Inhibition of rat hepatic mixed function oxidases by antimalarial drugs: selectivity for cytochromes P-450 and P-448. Chem. Biol. Interact.51(3),285–294 (1984).
Medline CASGoogle Scholar
160 Thabrew MI, Nashiru TO, Emerole GO: Drug induced alterations in some rat hepatic microsomal components: a comparative study of four structurally different antimalarials. Comp. Biochem. Physiol. C,81(1),133–138 (1985).
Medline CASGoogle Scholar
161 Young RA, Mehendale HM: Effect of cytochrome P-450 and flavin-containing monooxygenase modifying factors on the in vitro metabolism of amiodarone by rat and rabbit. Drug Metab. Dispos.15(4),511–517 (1987).
Medline CASGoogle Scholar
162 Nagai J, Tanaka M, Hibasami H, Ikeda T: Inhibition of oxidative hemolysis and lipid peroxidation by mepacrine. J. Biochem. (Tokyo)89(4),1143–1148 (1981).
Medline CASGoogle Scholar
163 Canonico PL, Judd AM, Koike K, Valdenegro CA, MacLeod RM: Arachidonate stimulates prolactin release in vitro: a role for the fatty acid and its metabolites as intracellular regulator(s) in mammotrophs. Endocrinology116(1),218–225 (1985).
Medline CASGoogle Scholar
164 Metz SA: Exogenous arachidonic acid promotes insulin release from intact or permeabilized rat islets by dual mechanisms. Putative activation of Ca²⁺ mobilization and protein kinase C: Diabetes37(11),1453–1469 (1988).
Medline CASGoogle Scholar
165 Thomson FJ, Johnson MS, Mitchell R, Wolbers B: Evidence for a role of phospholipase A2 in the mechanism of LHRH priming in rat anterior pituitary tissue. J. Endocrinol.141(1),15–31 (1994).
Medline CASGoogle Scholar
166 Thomson FJ, Mitchell R: Differential involvement of phospholipase A2 in phorbol ester-induced luteinizing hormone and growth hormone release from rat anterior pituitary tissue. Mol. Cell. Endocrinol.95(1–2),75–83 (1993).
Medline CASGoogle Scholar
167 Ma K, Sourkes TL: Inhibition of diamine oxidase by antimalarial drugs. Agents Actions10(5),395–398 (1980).
Medline CASGoogle Scholar
168 Otamiri TA: Influence of quinacrine on plasma malondialdehyde after small intestinal ischemia and reperfusion. Circ. Shock24(1),63–69 (1988).
Medline CASGoogle Scholar
169 Al Moutaery AR, Tariq M: Effect of quinacrine, a phospholipase A2 inhibitor on stress and chemically induced gastroduodenal ulcers. Digestion58(2),129–137 (1997).
Medline CASGoogle Scholar
170 Horton JR, Sawada K, Nishibori M, Zhang X, Cheng X: Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. Structure (Camb.)9(9),837–849 (2001).
Medline CASGoogle Scholar
171 Preclik G, Stange EF, Ditschuneit H: Activation of PGE2-secretion from gastric mucosa by a type I phospholipase C is mediated by a direct release of arachidonic acid. Clin. Physiol. Biochem.9(2),78–86 (1992).
Medline CASGoogle Scholar
172 Hou W, Arita Y, Morisset J: Endogenous arachidonic acid release and pancreatic amylase secretion. Pancreas14(3),301–308 (1997).
Medline CASGoogle Scholar
173 Meneghini R: Repair replication of opossum lymphocyte DNA: effect of compounds that bind to DNA. Chem. Biol. Interact.8(2),113–126 (1974).
Medline CASGoogle Scholar
174 Hart JW, Hartley-Asp B: Induction of micronuclei in the mouse. Revised timing of the final stage of erythropoiesis. Mutat. Res.120(2–3),127–132 (1983).
Medline CASGoogle Scholar
175 Xamena N, Creus A, Velazquez A, Marcos R: Testing of chloroquine and quinacrine for mutagenicity in Drosophila melanogaster. Mutat. Res.158(3),177–180 (1985).
Medline CASGoogle Scholar

Vol. 5, No. 10

Metrics

Downloaded 357 times

History

Published online 15 December 2009

Published in print December 2009

Information

Keywords

Acknowledgements

I would like to acknowledge Drs Patti Baker (Cleveland BioLabs, Inc), Andrei Gudkov and Misha Blagosklonny (Roswell Park Cancer Institute) for productive discussions and helpful suggestions in writing of this manuscript. The studies mentioned in the review as unpublished or submitted were partially carried out using NIH Grant R42 CA 110400-01 to the author.

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents

Abstract

Bibliography